Prostate-specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder.
Fifteen urinary bladder adenocarcinomas and nine bladder tumors with mixed glandular and transitional features were studied with antisera to prostate-specific antigen (PSA) and prostate-specific acid phosphatase (PSAP). The study was repeated with antisera from different companies to assess the reproducibility of the results. Of the 11 adenocarcinomas in men, three were positive for PSAP. Of the five tumors with mixed glandular and transitional features in men, one showed PSAP immunoreactivity. In the female subjects, PSAP staining was seen in two of the four adenocarcinomas and two of the four mixed glandular and transitional cell carcinomas. None of the tumors seen in either the male or female groups was considered positive for PSA.
D000135:Acid Phosphatase / Q000097:blood*; D000230:Adenocarcinoma / Q000175:diagnosis / Q000276:immunology*; D000941:Antigens / Q000276:immunology; D004796:Clinical Enzyme Tests; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D013194:Staining and Labeling; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000276:immunology*
D000941:Antigens; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen